Related Experiment Video
Updated: May 17, 2026
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
Clinical Outcomes of Catheter Ablation for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
Siddharth Agarwal1, Harsh P Patel1, Rutvij Patel2
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Insights
Catheter ablation significantly lowers mortality and heart failure exacerbations in hypertrophic cardiomyopathy patients with atrial fibrillation compared to anti-arrhythmic drugs.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is prevalent in hypertrophic cardiomyopathy (HCM) patients, increasing morbidity and heart failure (HF) risk.
- Limited data exist comparing long-term outcomes of catheter ablation versus anti-arrhythmic drug (AAD) therapy for AF in HCM.
Purpose of the Study:
- To compare long-term clinical outcomes of catheter ablation versus AAD therapy in patients with HCM and AF.
- Evaluate mortality, HF exacerbations, and AAD-related adverse events.
Main Methods:
- Retrospective cohort study using the TriNetX Research Network (2010-2020).
- Adult patients with HCM and AF treated with catheter ablation or AADs.
- Propensity score matching (PSM) and survival analysis were employed.
Main Results:
- Catheter ablation was linked to lower all-cause mortality (9.5% vs. 14.8%) and reduced HF exacerbations (38.4% vs. 43.3%) compared to AADs.
- Ablation also decreased AAD-related adverse events (8.4% vs. 11.2%).
- All-cause hospitalization and ischemic stroke rates were similar between groups.
Conclusions:
- Catheter ablation demonstrates significant clinical benefits over AAD therapy in HCM patients with AF.
- Reduced mortality, HF hospitalizations, and AAD adverse events were observed.
- Further prospective studies are warranted to confirm these real-world findings.
Background:
Atrial fibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and is associated with increased morbidity, heart failure (HF) exacerbations, and adverse long-term outcomes. Although catheter ablation is an established rhythm-control strategy, data comparing its long-term clinical outcomes with anti-arrhythmic drug (AAD) therapy in patients with HCM remain limited.
Objective:
To compare long-term clinical outcomes of catheter ablation versus medical therapy with AADs in patients with HCM and AF.
Methods:
We conducted a retrospective cohort study using the TriNetX Research Network, a global federated database of electronic health records. Adult patients with HCM and AF between January 2010 and December 2020 were identified and stratified according to treatment with catheter ablation or AAD therapy. Outcomes included all-cause mortality, HF exacerbations, AAD-related adverse events, all-cause hospitalization, ischemic stroke, repeat ablation, need for cardioversion, need for long-term AAD use, and atrioventricular nodal ablation. A 1:1 propensity score matching (PSM) analysis was performed to balance baseline characteristics. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate hazard ratios (HRs).
Results:
After PSM, 3144 patients were included (1572 in each cohort) with a mean follow-up of approximately 3.4 years. Catheter ablation was associated with lower all-cause mortality compared with AAD therapy (9.5% vs. 14.8%; HR: 0.60; 95% CI: 0.49-0.74; p < 0.001). Ablation was also associated with reduced risk of HF exacerbations (38.4% vs. 43.3%; HR: 0.79; 95% CI: 0.71-0.88; p < 0.001) and fewer AAD-related adverse events (8.4% vs. 11.2%; HR: 0.71; 95% CI: 0.55-0.93; p = 0.011). Rates of all-cause hospitalization (HR: 0.93; p = 0.11) and ischemic stroke (HR: 0.78; p = 0.10) were similar between groups.
Conclusion:
In this large real-world cohort of patients with HCM and AF, catheter ablation was associated with lower mortality, reduced HF hospitalizations, and decreased AAD therapy-related adverse events, as compared with medical therapy. These findings suggest that catheter ablation may provide meaningful clinical benefits in selected patients with HCM and AF, although prospective studies are needed to confirm these observations.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System